Kissei Pharmaceutical Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Mutsuo Kanzawa
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 42.7yrs |
| CEO ownership | 3.6% |
| Management average tenure | 4.7yrs |
| Board average tenure | 9.7yrs |
Recent management updates
Recent updates
Earnings Miss: Kissei Pharmaceutical Co., Ltd. Missed EPS By 20% And Analysts Are Revising Their Forecasts
Feb 05
Kissei Pharmaceutical (TSE:4547) Has Announced A Dividend Of ¥45.00
Jan 01Kissei Pharmaceutical (TSE:4547) Will Pay A Dividend Of ¥45.00
Dec 18Kissei Pharmaceutical (TSE:4547) Will Pay A Dividend Of ¥45.00
Dec 04Weak Statutory Earnings May Not Tell The Whole Story For Kissei Pharmaceutical (TSE:4547)
Nov 27Kissei Pharmaceutical (TSE:4547) Will Pay A Larger Dividend Than Last Year At ¥45.00
Sep 24Kissei Pharmaceutical (TSE:4547) Is Increasing Its Dividend To ¥45.00
Sep 09Kissei Pharmaceutical's (TSE:4547) Dividend Will Be Increased To ¥45.00
Jul 25Kissei Pharmaceutical (TSE:4547) Will Pay A Larger Dividend Than Last Year At ¥45.00
Jul 11Kissei Pharmaceutical's (TSE:4547) Shareholders May Want To Dig Deeper Than Statutory Profit
May 21Kissei Pharmaceutical Co., Ltd. (TSE:4547) Yearly Results: Here's What Analysts Are Forecasting For This Year
May 09Kissei Pharmaceutical (TSE:4547) Is Due To Pay A Dividend Of ¥41.00
Mar 27Kissei Pharmaceutical (TSE:4547) Is Due To Pay A Dividend Of ¥41.00
Mar 13Kissei Pharmaceutical (TSE:4547) Has Announced A Dividend Of ¥41.00
Feb 27CEO
Mutsuo Kanzawa (75 yo)
42.7yrs
Tenure
Mr. Mutsuo Kanzawa is Chief Executive Officer of Kissei Pharmaceutical Co. Ltd and served as its President since June 1992. Mr. Kanzawa has been the Chairman of Kissei Pharmaceutical Co. Ltd. since June 20...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | no data | no data | 3.6% ¥ 5.5b | |
| President | 2.7yrs | no data | 0.038% ¥ 58.7m | |
| GM of Financial Management Department | 12.7yrs | no data | 0.021% ¥ 32.4m | |
| Senior Advisor & Director | 14.7yrs | no data | 0.030% ¥ 45.9m | |
| Executive VP & Director | 12.7yrs | no data | 0.028% ¥ 42.4m | |
| Executive MD & Director | 4.7yrs | no data | 0.037% ¥ 56.1m | |
| GM of Pharmaceutical Sales Headquarters & Director | 2.7yrs | no data | 0.0040% ¥ 6.1m | |
| GM of Research Division & Director | 2.7yrs | no data | 0.0042% ¥ 6.5m |
4.7yrs
Average Tenure
62.5yo
Average Age
Experienced Management: 4547's management team is considered experienced (4.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 42.7yrs | no data | 3.6% ¥ 5.5b | |
| President | 13.1yrs | no data | 0.038% ¥ 58.7m | |
| GM of Financial Management Department | 6.7yrs | no data | 0.021% ¥ 32.4m | |
| Senior Advisor & Director | 16.7yrs | no data | 0.030% ¥ 45.9m | |
| Executive VP & Director | 12.7yrs | no data | 0.028% ¥ 42.4m | |
| Executive MD & Director | 10.7yrs | no data | 0.037% ¥ 56.1m | |
| GM of Pharmaceutical Sales Headquarters & Director | 2.7yrs | no data | 0.0040% ¥ 6.1m | |
| GM of Research Division & Director | 2.7yrs | no data | 0.0042% ¥ 6.5m | |
| Independent Outside Director | 10.7yrs | no data | 0.0089% ¥ 13.6m | |
| Independent Outside Director | 4.7yrs | no data | 0.0040% ¥ 6.1m | |
| Independent Outside Director | 8.7yrs | no data | 0.012% ¥ 18.3m | |
| Independent Outside Director | 2.7yrs | no data | 0.0028% ¥ 4.3m |
9.7yrs
Average Tenure
63.5yo
Average Age
Experienced Board: 4547's board of directors are considered experienced (9.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/22 05:03 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kissei Pharmaceutical Co., Ltd. is covered by 17 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ritsuo Watanabe | BofA Global Research |
| Hidemaru Yamaguchi | Citigroup Global Markets Japan Inc. |
| Hidemaru Yamaguchi | Citigroup Inc |